紫杉醇脂质体加顺铂联合放疗同期治疗恶性肿瘤的近期疗效和不良反应

The response and toxicity of paclitaxel liposomes plus cisplatin combined with radiotherapy for patients with malignant tumors

目的评价紫杉醇脂质体加顺铂联合放疗同期治疗恶性肿瘤的近期疗效和不良反应。方法26例恶性肿瘤患者采用紫杉醇脂质体联合顺铂(DDP)化疗2～4周期,第1天给予紫杉醇脂质体135mg/m2;第2～5天给予DDP30mg/m2,同期给予放射治疗。结果26例患者中可评价近期疗效16例:完全缓解(CR)4例(25.0%),部分缓解(PR)8例(50.0%),稳定(SD)2例(12.50%),进展(PD)2例(12.5%),有效率(RR)为75.0%(12/16),临床获益率(CBR)为87.5%(13/16),其中鼻咽癌的有效率(RR)达到100%。不良反应主要为血液学毒性反应,以中性粒细胞减少为著,多数达Ⅱ、Ⅲ度反应。非血液学毒性反应中脱发(42.3%)、肝功能轻度损伤(30.8%)、口腔溃疡(26.9%)发生率较高。结论紫杉醇脂质体加顺铂方案结合同期放疗治疗恶性肿瘤近期疗效较好,不良反应可以耐受。

Objictive Valuated the response and toxicity of paclitaxel liposomal plus cisplatin combined with radiotherapy for patients with malignant tumors.Methods 26 cases of malignant tumors treated with liposomal paclitaxel and cisplatin（DDP） chemotherapy for 2 to 4 cycles,the first day gave paclitaxel liposome 135mg/m2;from the second to the fifth days gaveDDP 30mg/m2,over the same period to gave radiation treatment.Results 16 of 26 patients could be evaluated response of treatment,4 cases（25.0%）of complete , response（CR） ,8 cases（50.0% ） of partial response（PR） ,2 cases（ 12.5% ） of stable disease（SD） ,2 cases （ 12.5% ） of progress disease （PD）. Efficiency （RR） was 75.0% （ 12/16 ）, clinical benefit rate （CBR） was 87.5% （13/16） ,in which efficiency of NPC（RR） to 100%. The main side reaction was haematological toxicity, notable with neutropenia, the majority reached Ⅱ-Ⅲ degree of reaction. For non-haematological toxicity, hair loss （42.3%） , mild liver damage（30. 8% ） ,oral ulcer（26.9% ） were showed. Conclusion The paclitaxel liposomes plus cisplatin combined with radiotherapy has better efficacy in treatment of malignant tumors, and side reaction can be well tolerated.